Abstract:This review article provides an overview of the recent advancements of imidazo[1,2‐a]pyridine (IP) derivatives such as Akt, phosphoinositide‐3‐kinase (PI3K), tubulin, and c‐MET inhibitors. The structures of the compounds, their structure–activity relationships, and docking studies were added to assist researchers in synthesizing precisely targeted drugs, utilizing IP as the main scaffold to treat cancer. Cancer ranks among the most life‐threatening diseases worldwide and is continuously affecting all age groups. Consequently, many research studies are being carried out to develop new cancer treatments, but many of them experience resistance and cause severe toxicity to the patients. Therefore, there is a continuous need to design novel anticancer agents that are target‐based, have a higher potency, and have minimal toxicity. The imidazo[1,2‐a]pyridine (IP) pharmacophore has been found to be a prominent moiety in the field of medicinal chemistry due to its vast biological properties. Also, it holds immense potential for combating cancer with minimal side effects, depending on the substitution patterns of the core structure. IPs exhibit significant capability in regulating various cellular pathways, offering possibilities for targeted anticancer effects. The present review summarizes the anticancer profile of numerous IP derivatives synthesized and developed by various researchers from 2016 till now, as inhibitors of phosphoinositide‐3‐kinase/mammalian target of rapamycin (PI3K/mTOR), protein kinase B/mammalian target of rapamycin (Akt/mTOR), aldehyde dehydrogenase (ALDH), and tubulin polymerization. This review provides a comprehensive analysis of the anticancer activity afforded by the discussed IP compounds, emphasizing the structure–activity‐relationships (SARs). The aim is also to underscore the potential therapeutic future of the IP moiety as a potent partial structure for upcoming cancer drug development and to aid researchers in the field of rational drug design.

Glycogen synthase kinase-3β inhibitors as a novel promising target in the treatment of cancer: Medicinal Chemistry Perspective

A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies

Development of small-molecule inhibitors that target PI3Kβ

Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer

GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties

Studies of glycogen synthase kinase-3 inhibitors

Identifying promising GSK3β inhibitors for cancer management: a computational pipeline combining virtual screening and molecular dynamics simulations

Small Molecules Targeting Phosphoinositide 3-Kinases

Glycogen synthase kinase-3: A potential target for diabetes

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5‐diamino‐n‐substituted Benzamide Derivatives As Novel GSK‐3β Small Molecule Inhibitors

Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment

Machine Learning Prediction and Simulation of Drugs Targeting GSK-3β in Breast Cancer

Identification, Structure Modification, and Characterization of Potential Small-Molecule SGK3 Inhibitors with Novel Scaffolds

Medicinal chemistry perspectives on recent advances in Src kinase inhibitors as a potential target for the development of anticancer agents: Biological profile, selectivity, structure‐activity relationship

A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions

Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies

Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays

Insights into medicinal attributes of imidazo[1,2‐a]pyridine derivatives as anticancer agents